1
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, December 26, 2006: US07153848 (54 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.


2
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, March 25, 2008: US07348425 (36 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds


3
Muzammil M Mansuri, John C Martin, Thomas W Hudyma, Joanne J Bronson, Louis M Ferrara: Phosphonomethoxy carbocyclic nucleosides and nucleotides. Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, Rega Stichting v z w, Mark L Bosse, April 28, 1998: US05744600 (28 worldwide citation)

A compound of the Formula I or Formula II ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, hydroxy, chlorine, fluorine, bromine, or an organic substituent having 1 to 5 carbon atoms and selected from acyloxy having a hydrocarbon stem of 1 to 4 carbon atoms, alkoxy, alkylthio, amino, ...


4

5
Nicholas A Meanwell, Robert G Gentles, Min Ding, John A Bender, John F Kadow, Piyasena Hewawasam, Thomas W Hudyma, Xiaofan Zheng: Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. July 15, 2008: US07399758 (14 worldwide citation)

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


6
Peter F Juby, Thomas W Hudyma, Richard A Partyka: Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity. Bristol Myers Company, David M Morse, November 28, 1978: US04127720 (13 worldwide citation)

A series of novel pyrimido[2,1-a]isoquinoline derivatives is provided for use as inhibitors of allergic reactions. The compounds exhibit antiallergy activity by both oral and parenteral routes of administration.


7
Murray A Kaplan, Thomas W Hudyma, Robert A Lipper, Kun M Shih, Susan D Boettger: Cefepime cephalosporin salts. Bristol Myers Company, Robert E Carnahan, March 20, 1990: US04910301 (12 worldwide citation)

Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. Th ...


8
John D Matiskella, Stanley V D Andrea, Thomas W Hudyma, Yasutsugu Ueda, Oak K Kim, Raymond F Miller, Shelley E Hoeft, Joanne J Bronson: Cephalosporin derivatives. Bristol Meyers Squibb Company, David N Morse, July 25, 2000: US06093712 (10 worldwide citation)

Provided are cephem derivatives represented by the general formula ##STR1## wherein Ar, R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.10 are as defined in the application. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resis ...


9
Carl P Bergstrom, Scott W Martin, Thomas W Hudyma: HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, November 25, 2008: US07456165 (9 worldwide citation)

The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


10
Carl P Bergstrom, John A Bender, Robert G Gentles, Piyasena Hewawasam, Thomas W Hudyma, John F Kadow, Scott W Martin, Alicia Regueiro Ren, Kap Sun Yeung, Yong Tu, Katharine A Grant Young, Xiaofan Zheng: Indolobenzazepine HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, January 6, 2009: US07473688 (9 worldwide citation)

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.